Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.

Theratechnologies Inc.’s THTX share price has surged by 28.57%, which has investors questioning if this is right time to sell ...

Weissman was jointly awarded the 2023 Nobel Prize in Medicine with Katalin Karikó for discoveries which made COVID-19 ...

Weight trajectories differed significantly among patients with HIV during the first year of ART, with no associations observed between weight gain and type of ART regimen.

Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in ...

In the second trial, 1.4% of those switching to islatravir and doravirine and 4.9% of those who remained on their ART had at least 50 copies/mL of HIV-1 RNA at 48 weeks, reported Chloe Orkin ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...